Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate
vaccine (PCV13) have been increasing over the last decade. No systematic reviews have …

Abstract Objectives Pneumococcal conjugate vaccines (PCVs) have significantly reduced
disease burden caused by Streptococcus pneumoniae, a leading cause of childhood …

Background Although pneumococcal conjugate vaccines (PCVs) have been available for
prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae …

Background Pneumococcal diseases cause substantial mortality, morbidity, and economic
burden. Evidence on data inputs for economic evaluations of interventions targeting …

Community-acquired pneumonia (CAP) places a considerable burden on society. A
substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae …

Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal
conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization …

Background: Each year in China, approximately 700,000 children under 5 years old are
diagnosed with pneumonia, and 30,000 die of the disease. Although 7-valent pneumococcal …

En el presente artículo se analizan algunos ejemplos del uso de evidencia generada por el
Instituto Nacional de Salud (INS) que el Ministerio de Salud del Perú ha realizado en los …

Background Pneumococcal pneumonia (PP) causes almost one in five deaths in children
younger than 5 years worldwide. In Latin America and the Caribbean (LAC), pneumonia …

Background Currently, two pediatric pneumococcal conjugate vaccines are available in the
private market of Malaysia—13-valent pneumococcal conjugate vaccine (PCV13) and …